日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 study

ACTIV-2 研究中急性 COVID 期间不同人群的病毒脱落和症状严重程度

Kung, Evelyn; Deo, Rinki; Choudhary, Manish C; Chew, Kara W; Evering, Teresa H; Ignacio, Rachel Bender; Jagannathan, Prasanna; Flynn, James P; Regan, James; Moser, Carlee; Giganti, Mark J; Hughes, Michael D; Ritz, Justin; Javan, Arzhang Cyrus; Greninger, Alexander L; Singh, Upinder; Fischer, William; Daar, Eric S; Wohl, David A; Eron, Joseph J; Currier, Judith S; Coombs, Robert W; Smith, Davey M; Li, Jonathan Z

Tracking inflammation status for improving patient prognosis: A review of current methods, unmet clinical needs and opportunities

追踪炎症状态以改善患者预后:现有方法、未满足的临床需求和机遇综述

Raju, Vidya; Reddy, Revanth; Javan, Arzhang Cyrus; Hajihossainlou, Behnam; Weissleder, Ralph; Guiseppi-Elie, Anthony; Kurabayashi, Katsuo; Jones, Simon A; Faghih, Rose T

Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial.

在随机安慰剂对照试验中,使用抗严重急性呼吸综合征冠状病毒 2 单克隆抗体疗法后出现病毒和症状反弹

Chew Kara W, McGinley Brooke, Moser Carlee, Li Jonathan Z, Evering Teresa H, Ritz Justin, Javan Arzhang Cyrus, Margolis David, Wohl David A, Hughes Michael D, Daar Eric S, Currier Judith S, Eron Joseph J, Smith Davey M

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

ACTIV-2 研究中,Tixagevimab/cilgavimab 或安慰剂治疗 COVID-19 的安全性、药代动力学以及中和抗体和抗药抗体

Bender Ignacio, Rachel A; Chew, Kara W; Moser, Carlee; Currier, Judith S; Eron, Joseph J; Javan, Arzhang Cyrus; Giganti, Mark J; Ritz, Justin; Gibbs, Michael; Kouekam, Hervé Tchouakam; Esser, Mark T; Daar, Eric S; Choudhary, Manish; Deo, Rinki; Fletcher, Courtney V; Li, Jonathan Z; Hughes, Michael D; Smith, Davey; Wohl, David Alain

Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy

通过肌内或静脉注射抗病毒单克隆抗体疗法快速清除可培养的SARS-CoV-2病毒

Deo, Rinki; Choudhary, Manish C; Glover, Owen T; Ignacio, Rachel Bender; Boucau, Julie; Chew, Kara W; Moser, Carlee; Currier, Judith S; Eron, Joseph J; Javan, Arzhang Cyrus; Giganti, Mark J; Aga, Evgenia; Gibbs, Michael; Cohen, Taylor; Streicher, Katie; Soboleva, Karina; Fletcher, Courtney V; Daar, Eric S; Greninger, Alexander L; Coombs, Robert W; Fischer, William; Hughes, Michael D; Smith, Davey; Wohl, David Alain; Barczak, Amy K; Li, Jonathan Z

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

在突发传染病大流行背景下实施无缝衔接的二/三期研究设计:从 ACTIV-2 平台 COVID-19 治疗试验中汲取的经验教训

Giganti, Mark J; Chew, Kara W; Moser, Carlee; Eron, Joseph J; Pinilla, Mauricio; Li, Jonathan Z; Ritz, Justin; Javan, Arzhang Cyrus; Wohl, David Alain; Daar, Eric S; Currier, Judith S; Smith, Davey M; Hughes, Michael D

Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trial

ACTIV-2 试验中,amubarvimab/romlusevimab 与安慰剂相比,对 COVID-19 急性期后结局(包括参与者报告的长期 COVID)的影响

Evering, Teresa H; Moser, Carlee; Jilg, Nikolaus; Ritz, Justin; Wohl, David A; Li, Jonathan Z; Margolis, David; Javan, Arzhang Cyrus; Eron, Joseph J; Currier, Judith S; Daar, Eric S; Smith, Davey M; Hughes, Michael D; Chew, Kara W

Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial

SAB-185治疗非住院COVID-19成年患者的安全性和有效性:一项随机临床试验

Chew, Kara W; Taiwo, Babafemi O; Moser, Carlee; Daar, Eric S; Wohl, David Alain; Ritz, Justin; Javan, Arzhang Cyrus; Li, Jonathan Z; Fischer, William; Greninger, Alexander L; Bausch, Christoph; Luke, Thomas; Call, Robert; Neytman, Gene; Giganti, Mark J; Fletcher, Courtney V; Hughes, Michael D; Eron, Joseph J; Currier, Judith S; Smith, Davey M

ACTIV trials: cross-trial lessons learned for master protocol implementation

ACTIV试验:从跨试验中汲取的经验教训对主方案实施的影响

Keshtkar-Jahromi, Maryam; Adam, Stacey J; Brar, Indira; Chung, Lucy K; Currier, Judith S; Daar, Eric S; Davey, Victoria J; Denning, Eileen T; Gelijns, Annetine C; Higgs, Elizabeth S; Jagannathan, Prasanna; Javan, Arzhang Cyrus; Jensen, Tomas O; Jilg, Nikolaus; Kalomenidis, Ioannis; Kim, Peter; Nayak, Seema U; Newell, Matthew; Taiwo, Babafemi O; Yokum, Tammy; Delph, Yvette

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

在一项 II 期试验中,对非住院 COVID-19 患者皮下注射联合 SARS-CoV-2 中和单克隆抗体 BMS-986414 (C135-LS) 和 BMS-986413 (C144-LS) 的安全性、有效性和药代动力学进行了评估

Corado, Katya C; Chew, Kara W; Giganti, Mark J; Mu, Ying; Fletcher, Courtney V; Currier, Judith S; Daar, Eric S; Wohl, David A; Li, Jonathan Z; Moser, Carlee B; Ritz, Justin; Javan, Arzhang Cyrus; Neytman, Gene; Caskey, Marina; Hughes, Michael D; Smith, Davey M; Eron, Joseph J